Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335198) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry' on Jan. 05.

Brief Summary: This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.

Study Start Date: Jan. 14

Study Type: INTERVENTIONAL

Condition: Non-alcoholic Fatty Liver Disease

Intervention: DRUG: Efimosfermin alfa

Efimosfermin alfa to be administered...